HRCR November 2021 Quiz

Editorial note: The following quiz is related to the article Ibrutinib-associated atrial fibrillation treatment with catheter ablation, by Kapoor and colleagues in the November 2021 issue of Heart Rhythm Case Reports.

Question 1: Which arrhythmia(s) can be seen in patients using tyrosine kinase inhibitors (TKIs) for cancer treatment?

Question 2: Which of the following related to atrial fibrillation (AF) management in patients taking Ibrutinib is true?

a. Uncontrolled AF rarely leads to treatment cessation of Ibrutinib
b. Rate control can be achieved with calcium channel blockers (i.e., diltiazem)
c. Bleeding risk with oral anticoagulant use for stroke prevention is similar to patients not on ibrutinib
d. Serum concentration of ibrutinib can be increased when concurrently treated with drugs that inhibit CYP3A4 activity such as amiodarone

Question 3: Which of the following is false regarding ibrutinib?

a. It inhibits Bruton's tyrosine kinase (BTK)
b. It is used to treat B-cell malignancies such as chronic lymphocytic leukemia, mantle cell lymphoma, and Waldenstrom’s macroglobulinemia
c. It is associated with increased rates of atrial fibrillation, up to 5-16%
d. It inhibits the p-glycoprotein and thereby decreases the level of serum digoxin